ChiCTR2600125117 版本V1.0 版本创建时间2026/05/21 14:54:08 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600125117 

最近更新日期:

Date of Last Refreshed on:

2026-05-21 14:53:50 

注册时间:

Date of Registration:

2026-05-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

饮水干预对肥胖儿童血糖调节

Public title:

Water Intake Intervention on Blood Glucose Regulation in Obese Children

注册题目简写:

English Acronym:

研究课题的正式科学名称:

水合状态对肥胖儿童和肽素、血糖调节影响及机制研究

Scientific title:

The effects and mechanism of hydration status on copeptin and glucose in obese children

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张建芬 

研究负责人:

张建芬 

Applicant:

Jianfen Zhang 

Study leader:

Jianfen Zhang 

申请注册联系人电话:

Applicant telephone:

+86 10 66237157

研究负责人电话:

Study leader's
telephone:

+86 10 6623 7157

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhangjf@ninh.chinacdc.cn

研究负责人电子邮件:

Study leader's E-mail:

zhangjf@ninh.chinacdc.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区南纬路27号

研究负责人通讯地址:

北京市西城区南纬路27号

Applicant address:

27 Nanwei Road, Xicheng District, Beijing, China

Study leader's address:

27 Nanwei Road, Xicheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国疾病预防控制中心营养与健康所

Applicant's institution:

National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention

研究负责人所在单位:

中国疾病预防控制中心营养与健康所

Affiliation of the Leader:

National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-011

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国疾病预防控制中心营养与健康所伦理委员会

Name of the ethic committee:

The Ethical Review Committee of National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention

伦理委员会批准日期:

Date of approved by ethic committee:

2025-05-15 00:00:00

伦理委员会联系人:

苑晓琳

Contact Name of the ethic committee:

Yuan Xiaolin

伦理委员会联系地址:

北京市西城区南纬路27号

Contact Address of the ethic committee:

27 Nanwei Road, Xicheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 66237032

伦理委员会联系人邮箱:

Contact email of the ethic committee:

yuanxl@ninh.chinacdc.cn

研究实施负责(组长)单位:

中国疾病预防控制中心营养与健康所

Primary sponsor:

National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention

研究实施负责(组长)单位地址:

北京市西城区南纬路27号

Primary sponsor's address:

27 Nanwei Road, Xicheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国疾病预防控制中心营养与健康所

具体地址:

北京市西城区南纬路27号

Institution
hospital:

National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention

Address:

27 Nanwei Road, Xicheng District, Beijing, China

经费或物资来源:

癌症、心脑血管、呼吸和代谢性疾病防治研究国家科技重大专项

Source(s) of funding:

National Science and Technology Major Project for Research on Prevention and Control of Cancer, Card

研究疾病:

水合状态、和肽素、血糖水平  

Target disease:

the levels of copeptin, blood glucose metabolic indices

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1、分析不同水合状态正常体重儿童与肥胖儿童和肽素、血糖、胰岛功能等差异及相关性,获得从水合状态和和肽素角度诊断糖代谢状态的可能性; 2、通过改善肥胖儿童水合状态,从而调整和肽素水平、血糖代谢指标,分析可能的机制,为将合理进行饮水干预纳入肥胖以及血糖异常生活方式干预提供科学依据。  

Objectives of Study:

1. To analyze the differences and correlations of copeptin, blood glucose and islet function among normal-weight and obese children under different hydration statuses, and explore the possibility of diagnosing glucose metabolic status from the perspectives of hydration status and copeptin. 2. To regulate copeptin levels and glucose metabolic indicators by improving the hydration status of obese children, and analyze the potential mechanisms, so as to provide scientific evidence for incorporating rational drinking water intervention into lifestyle intervention for obesity and abnormal glucose metabolism.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

正常体重儿童: 1.年龄 9-10 岁且 BMI 正常; 2.无已知的代谢性疾病; 3.自愿参与实验,并签署知情同意书。 肥胖儿童: 1.年龄 9-10 岁(小学 3-4 年级);依据《学龄儿童青 少年超重与肥胖筛查》(WS/T 586)判定肥胖; 2.无已知的代谢性疾病; 3.自愿参与实验,并签署知情同意书。

Inclusion criteria

Normal-weight children: 1. Aged 9–10 years with a normal BMI; 2. No known metabolic diseases; 3. Voluntary participation in the experiment, with informed consent signed. Obese children: 1. Aged 9–10 years (grades 3–4 in primary school), obesity determined according to the Screening for Overweight and Obesity Among School-Aged Children and Adolescents (WS/T 586); 2. No known metabolic diseases; 3. Voluntary participation in the experiment, with informed consent signed.

排除标准:

1.二级以上医院诊断的口腔、肝、肾、心血管疾病、糖尿病、 慢性泌尿系感染和自身免疫性疾病及贫血、甲状腺功能异常者; 2.长期口服利尿剂、糖皮质激素等药物; 3.3 个月内参加过其他临床试验。

Exclusion criteria:

1. Individuals diagnosed with oral, hepatic, renal, cardiovascular diseases, diabetes, chronic urinary tract infections, autoimmune diseases, anemia, or thyroid dysfunction at or above secondary-level hospitals; 2. Those on long-term oral medication such as diuretics or glucocorticoids; 3. Participation in other clinical trials within the past 3 months.

研究实施时间:

Study execute time:

From 2025-05-01 00:00:00 To 2028-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-01 00:00:00 To 2026-06-30 00:00:00

干预措施:

Interventions:

组别:

饮水干预组

样本量:

120

Group:

Water Intervention group

Sample size:

干预措施:

保持适宜饮水量

干预措施代码:

Intervention:

keep an adequate water intake

Intervention code:

组别:

对照组

样本量:

120

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

no intervention

Intervention code:

组别:

正常体重儿童组

样本量:

200

Group:

Normal-weight children group

Sample size:

干预措施:

干预措施代码:

Intervention:

no intervention

Intervention code:

组别:

肥胖儿童组

样本量:

200

Group:

Obese children group

Sample size:

干预措施:

干预措施代码:

Intervention:

no intervention

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

营养与健康所 

单位级别:

 

Institution
hospital:

National Institute for Nutrition and Health,China CDC

Level of the institution:

测量指标:

Outcomes:

指标中文名:

渗透压

指标类型:

主要指标

Outcome:

osmolality

Type:

Primary indicator

测量时间点:

基线、干预后

测量方法:

冰点下降法

Measure time point of outcome:

baseline、after intervention

Measure method:

freezing point depression method

指标中文名:

和肽素

指标类型:

主要指标

Outcome:

copeptin

Type:

Primary indicator

测量时间点:

基线、干预后

测量方法:

化学发光法/酶联免疫法

Measure time point of outcome:

baseline、after intervention

Measure method:

Chemiluminescence immunoassay / Enzyme-linked immunosorbent assay (ELISA)

指标中文名:

血糖

指标类型:

主要指标

Outcome:

glucose

Type:

Primary indicator

测量时间点:

基线、干预后

测量方法:

己糖激酶法

Measure time point of outcome:

baseline、after intervention

Measure method:

Hexokinase method

指标中文名:

胰岛素

指标类型:

次要指标

Outcome:

Insulin

Type:

Secondary indicator

测量时间点:

基线、干预后

测量方法:

化学发光法

Measure time point of outcome:

baseline、after intervention

Measure method:

Chemiluminescence immunoassay

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 7 years
最大 Max age 15 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由项目组人员采用随机数字表法进行随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomized grouping was conducted by project team members using a random number table method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

双盲

Blinding:

Double blind

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

数据均由项目负责人保存,可直接从项目负责人处获取数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The data is saved to the project leader and can be accessed directly from the project leader

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据由项目负责人保存

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data is saved by the project leader

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-05-21 14:53:50